An orally administered butyrate-releasing derivative reduces neutrophil recruitment and inflammation in dextran sulphate sodium-induced murine colitis

British Journal of Pharmacology

Volumn 174, Issue 11, 2017, Pages 1484-1496

  Simeoli, Raffaele ^a,b   Mattace Raso, Giuseppina ^a   Pirozzi, Claudio ^a   Lama, Adriano ^a   Santoro, Anna ^a   Russo, Roberto ^a   Montero Melendez, Trinidad ^b   Berni Canani, Roberto ^a   Calignano, Antonio ^a   Perretti, Mauro ^b   Meli, Rosaria ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; DEXTRAN SULFATE; HISTONE DEACETYLASE 9; HISTONE H3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; N (1 CARBAMOYL 2 PHENYLETHYL)BUTYRAMIDE; OCCLUDIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN ZO1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; BUTYRIC ACID DERIVATIVE; N-(1-CARBAMOYL-2-PHENYL-ETHYL)BUTYRAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL INFILTRATION; COLITIS; CONTROLLED STUDY; DRUG EFFECT; HISTONE ACETYLATION; MALE; MOUSE; NEUTROPHIL; NONHUMAN; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TIGHT JUNCTION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; DISEASE MODEL; DRUG EFFECTS; GENETICS; INFLAMMATION; NEUTROPHIL CHEMOTAXIS; ORAL DRUG ADMINISTRATION; PATHOLOGY; TIME FACTOR;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; BUTYRATES; COLITIS; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; INFLAMMATION; MALE; MICE; MICE, INBRED BALB C; NEUTROPHIL INFILTRATION; NF-KAPPA B; PPAR GAMMA; TIME FACTORS; UP-REGULATION;

EID: 84996564005     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13637     Document Type: Article

References (70)

1. Alexander SPH, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E et al. (2015a). The Concise Guide to PHARMACOLOGY 2015/16: Overview. Br J Pharmacol 172: 5729–5143.
2. Alexander SPH, Davenport AP, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015b). The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. Br J Pharmacol 172: 5744–5869.
3. Alexander SPH, Cidlowski JA, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015c). The Concise Guide to PHARMACOLOGY 2015/16: Nuclear hormone receptors. Br J Pharmacol 172: 5956–5978.
4. Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015d). The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol 172: 6024–6109.
5. Alexander SPH, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E et al. (2015e). The Concise Guide to PHARMACOLOGY 2015/16: Transporters. Br J Pharmacol 172: 6110–6202.
6. Amre DK, D'Souza S, Morgan K, Seidman G, Lambrette P, Grimard G et al. (2007). Imbalances in dietary consumption of fatty acids, vegetables, and fruits are associated with risk for Crohn's disease in children. Am J Gastroenterol 102: 2016–2025.
7. Ananthakrishnan AN, Khalili H, Konijeti GG, Higuchi LM, de Silva P, Korzenik JR et al. (2013). A prospective study of long-term intake of dietary fiber and risk of Crohn's disease and ulcerative colitis. Gastroenterology 145: 970–977.
8. Bindels LB, Dewulf EM, Delzenne NM (2013). GPR43/FFA2: physiopathological relevance and therapeutic prospects. Trends Pharmacol Sci 34: 226–232.
9. Borthakur A, Saksena S, Gill RK, Alrefai WA, Ramaswamy K, Dudeja PK (2008). Regulation of monocarboxylate transporter 1 (MCT1) promoter by butyrate in human intestinal epithelial cells: involvement of NF-kappaB pathway. J Cell Biochem 103: 1452–1463.
10. Borthakur A, Priyamvada S, Kumar A, Natarajan AA, Gill RK, Alrefai WA et al. (2012). A novel nutrient sensing mechanism underlies substrate-induced regulation of monocarboxylate transporter-1. Am J Physiol Gastrointest Liver Physiol 303: G1126–G1133.
11. Bradley PP, Priebat DA, Christensen RD, Rothstein G (1982). Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 78: 206–209.
12. Breuer RI, Soergel KH, Lashner BA, Christ ML, Hanauer SB, Vanagunas A et al. (1997). Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomised, placebo controlled trial. Gut 40: 485–491.
13. Canani RB, Costanzo MD, Leone L, Pedata M, Meli R, Calignano A (2011). Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J Gastroenterol 17: 1519–1528.
14. Chang PV, Hao L, Offermanns S, Medzhitov R (2014). The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc Natl Acad Sci U S A 111: 2247–2252.
15. Cooper HS, Murthy SN, Shah RS, Sedergran DJ (1993). Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 69: 238–249.
16. Cuff MA, Lambert DW, Shirazi-Beechey SP (2002). Substrate-induced regulation of the human colonic monocarboxylate transporter, MCT1. J Physiol 539: 361–371.
17. Curtis MJ, Bond RA, Spina D, Ahluwalia A, Alexander SP, Giembycz MA et al. (2015). Experimental design and analysis and their reporting: new guidance for publication in BJP. Br J Pharmacol 172: 3461–3471.
18. De Preter V, Arijs I, Windey K, Vanhove W, Vermeire S, Schuit F et al. (2012). Impaired butyrate oxidation in ulcerative colitis is due to decreased butyrate uptake and a defect in the oxidation pathway. Inflamm Bowel Dis 18: 1127–1136.
19. de Zoeten EF, Wang L, Sai H, Dillmann WH, Hancock WW (2010). Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice. Gastroenterology 138: 583–594.
20. Desreumaux P, Dubuquoy L, Nutten S, Peuchmaur M, Englaro W, Schoonjans K et al. (2001). Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies. J Exp Med 193: 827–838.
21. Dieleman LA, Pena AS, Meuwissen SG, van Rees EP (1997). Role of animal models for the pathogenesis and treatment of inflammatory bowel disease. Scand J Gastroenterol Suppl 223: 99–104.
22. Dubuquoy L, Jansson EA, Deeb S, Rakotobe S, Karoui M, Colombel JF et al. (2003). Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. Gastroenterology 124: 1265–1276.
23. Dubuquoy L, Rousseaux C, Thuru X, Peyrin-Biroulet L, Romano O, Chavatte P et al. (2006). PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut 55: 1341–1349.
24. Fernandez-Banares F, Hinojosa J, Sanchez-Lombrana JL, Navarro E, Martinez-Salmeron JF, Garcia-Puges A et al. (1999). Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish group for the study of Crohn's disease and ulcerative colitis (GETECCU). Am J Gastroenterol 94: 427–433.
25. Gerke V, Creutz CE, Moss SE (2005). Annexins: linking Ca2+ signalling to membrane dynamics. Nat Rev Mol Cell Biol 6: 449–461.
26. Geuking MB, Koller Y, Rupp S, McCoy KD (2014). The interplay between the gut microbiota and the immune system. Gut microbes 5: 411–418.
27. Glauben R, Batra A, Fedke I, Zeitz M, Lehr HA, Leoni F et al. (2006). Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J Immunol 176: 5015–5022.
28. Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ (2008). Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther 27: 104–119.
29. Hamer HM, Jonkers DM, Bast A, Vanhoutvin SA, Fischer MA, Kodde A et al. (2009). Butyrate modulates oxidative stress in the colonic mucosa of healthy humans. Clin Nutr 28: 88–93.
30. Hamer HM, Jonkers DM, Vanhoutvin SA, Troost FJ, Rijkers G, de Bruine A et al. (2010). Effect of butyrate enemas on inflammation and antioxidant status in the colonic mucosa of patients with ulcerative colitis in remission. Clin Nutr 29: 738–744.
31. Hanai H, Kanauchi O, Mitsuyama K, Andoh A, Takeuchi K, Takayuki I et al. (2004). Germinated barley foodstuff prolongs remission in patients with ulcerative colitis. Int J Mol Med 13: 643–647.
32. Hou JK, Abraham B, El-Serag H (2011). Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. Am J Gastroenterol 106: 563–573.
33. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577–1579.
34. Klemashevich C, Wu C, Howsmon D, Alaniz RC, Lee K, Jayaraman A (2014). Rational identification of diet-derived postbiotics for improving intestinal microbiota function. Curr Opin Biotechnol 26: 85–90.
35. Leoni G, Alam A, Neumann PA, Lambeth JD, Cheng G, McCoy J et al. (2013). Annexin A1, formyl peptide receptor, and NOX1 orchestrate epithelial repair. J Clin Invest 123: 443–454.
36. Maslowski KM, Vieira AT, Ng A, Kranich J, Sierro F, Yu D et al. (2009). Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 461: 1282–1286.
37. Mattace Raso G, Simeoli R, Russo R, Iacono A, Santoro A, Paciello O et al. (2013). Effects of sodium butyrate and its synthetic amide derivative on liver inflammation and glucose tolerance in an animal model of steatosis induced by high fat diet. PLoS One 8: e68626.
38. McDermott AJ, Huffnagle GB (2014). The microbiome and regulation of mucosal immunity. Immunology 142: 24–31.
39. McGrath JC, Lilley E (2015). Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP. Br J Pharmacol 172: 3189–3193.
40. Mishiro T, Kusunoki R, Otani A, Ansary MM, Tongu M, Harashima N et al. (2013). Butyric acid attenuates intestinal inflammation in murine DSS-induced colitis model via milk fat globule-EGF factor 8. Lab Invest 93: 834–843.
41. Mulla A, Leroux C, Solito E, Buckingham JC (2005). Correlation between the antiinflammatory protein annexin 1 (lipocortin 1) and serum cortisol in subjects with normal and dysregulated adrenal function. J Clin Endocrinol Metab 90: 557–562.
42. Nusrat A, Parkos CA, Liang TW, Carnes DK, Madara JL (1997). Neutrophil migration across model intestinal epithelia: monolayer disruption and subsequent events in epithelial repair. Gastroenterology 113: 1489–1500.
43. Peng L, Li ZR, Green RS, Holzman IR, Lin J (2009). Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr 139: 1619–1625.
44. Perretti M, Croxtall JD, Wheller SK, Goulding NJ, Hannon R, Flower RJ (1996). Mobilizing lipocortin 1 in adherent human leukocytes downregulates their transmigration. Nat Med 2: 1259–1262.
45. Perretti M, Christian H, Wheller SK, Aiello I, Mugridge KG, Morris JF et al. (2000). Annexin I is stored within gelatinase granules of human neutrophil and mobilized on the cell surface upon adhesion but not phagocytosis. Cell Biol Int 24: 163–174.
46. Raab Y, Gerdin B, Ahlstedt S, Hallgren R (1993). Neutrophil mucosal involvement is accompanied by enhanced local production of interleukin-8 in ulcerative colitis. Gut 34: 1203–1206.
47. Russo R, De Caro C, Avagliano C, Cristiano C, La Rana G, Mattace Raso G et al. (2016). Sodium butyrate and its synthetic amide derivative modulate nociceptive behaviors in mice. Pharmacol Res 103: 279–291.
48. Scheppach W, Sommer H, Kirchner T, Paganelli GM, Bartram P, Christl S et al. (1992). Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis. Gastroenterology 103: 51–56.
49. Schwab M, Reynders V, Ulrich S, Zahn N, Stein J, Schroder O (2006). PPARgamma is a key target of butyrate-induced caspase-3 activation in the colorectal cancer cell line Caco-2. Apoptosis 11: 1801–1811.
50. Schwab M, Reynders V, Loitsch S, Steinhilber D, Stein J, Schroder O (2007). Involvement of different nuclear hormone receptors in butyrate-mediated inhibition of inducible NF kappa B signalling. Mol Immunol 44: 3625–3632.
51. Segain JP, Raingeard de la Bletiere D, Bourreille A, Leray V, Gervois N, Rosales C et al. (2000). Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut 47: 397–403.
52. Shimoyama T, Sawada K, Hiwatashi N, Sawada T, Matsueda K, Munakata A et al. (2001). Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apher 16: 1–9.
53. Simeoli R, Mattace Raso G, Lama A, Pirozzi C, Santoro A, Di Guida F et al. (2015). Preventive and therapeutic effects of Lactobacillus paracasei B21060-based synbiotic treatment on gut inflammation and barrier integrity in colitic mice. J Nutr 145: 1202–1210.
54. Sina C, Gavrilova O, Forster M, Till A, Derer S, Hildebrand F et al. (2009). G protein-coupled receptor 43 is essential for neutrophil recruitment during intestinal inflammation. J Immunol 183: 7514–7522.
55. Singh N, Gurav A, Sivaprakasam S, Brady E, Padia R, Shi H et al. (2014). Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity 40: 128–139.
56. Sipponen T (2013). Diagnostics and prognostics of inflammatory bowel disease with fecal neutrophil-derived biomarkers calprotectin and lactoferrin. Dig Dis 31: 336–344.
57. Smith JW, Castro GA (1978). Relation of peroxidase activity in gut mucosa to inflammation. Am J Physiol 234: R72–R79.
58. Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly YM et al. (2013). The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 341: 569–573.
59. Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SP et al. (2016). The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucl Acids Res 44: D1054–D1068.
60. Steinhart AH, Hiruki T, Brzezinski A, Baker JP (1996). Treatment of left-sided ulcerative colitis with butyrate enemas: a controlled trial. Aliment Pharmacol Ther 10: 729–736.
61. Steliou K, Boosalis MS, Perrine SP, Sangerman J, Faller DV (2012). Butyrate histone deacetylase inhibitors. Biores Open Access 1: 192–198.
62. Thibault R, De Coppet P, Daly K, Bourreille A, Cuff M, Bonnet C et al. (2007). Down-regulation of the monocarboxylate transporter 1 is involved in butyrate deficiency during intestinal inflammation. Gastroenterology 133: 1916–1927.
63. Thibault R, Blachier F, Darcy-Vrillon B, de Coppet P, Bourreille A, Segain JP (2010). Butyrate utilization by the colonic mucosa in inflammatory bowel diseases: a transport deficiency. Inflamm Bowel Dis 16: 684–695.
64. Tsou CL, Peters W, Si Y, Slaymaker S, Aslanian AM, Weisberg SP et al. (2007). Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites. J Clin Invest 117: 902–909.
65. Vergnolle N, Comera C, Bueno L (1995). Annexin 1 is overexpressed and specifically secreted during experimentally induced colitis in rats. Eur J Biochem 232: 603–610.
66. Vergnolle N, Pages P, Guimbaud R, Chaussade S, Bueno L, Escourrou J et al. (2004). Annexin 1 is secreted in situ during ulcerative colitis in humans. Inflamm Bowel Dis 10: 584–592.
67. Vernia P, Annese V, Bresci G, d'Albasio G, D'Inca R, Giaccari S et al. (2003). Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: results of a multicentre trial. Eur J Clin Invest 33: 244–248.
68. Vieira EL, Leonel AJ, Sad AP, Beltrao NR, Costa TF, Ferreira TM et al. (2012). Oral administration of sodium butyrate attenuates inflammation and mucosal lesion in experimental acute ulcerative colitis. J Nutr Biochem 23: 430–436.
69. Wedlake L, Slack N, Andreyev HJ, Whelan K (2014). Fiber in the treatment and maintenance of inflammatory bowel disease: a systematic review of randomized controlled trials. Inflamm Bowel Dis 20: 576–586.
70. Yan Y, Kolachala V, Dalmasso G, Nguyen H, Laroui H, Sitaraman SV et al. (2009). Temporal and spatial analysis of clinical and molecular parameters in dextran sodium sulfate induced colitis. PLoS One 4: e6073.